scholarly journals Isolated Granulocytic Sarcoma of the Breast after Allogeneic Stem Cell Transplantation: A Rare Involvement Also Detected by 18FDG-PET/CT

2014 ◽  
Vol 31 (1) ◽  
pp. 88-91 ◽  
Author(s):  
Eren Gündüz ◽  
Meltem Olga Akay ◽  
Mustafa Karagülle ◽  
İlknur Sivrikoz Ak
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Granulocytic Sarcoma ◽  
18Fdg Pet ◽  
Pet Ct

scholarly journals Extramedullary Relapse in a CML Patient after Allogeneic Stem Cell Transplantation

2017 ◽  
Vol 2017 ◽  
pp. 1-3 ◽  
Author(s):  
Asu Fergun Yilmaz ◽  
Nur Soyer ◽  
Nazan Ozsan ◽  
Seckin Cagirgan ◽  
Ajda Gunes ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Kinase Inhibitors ◽  
Bone Marrow Involvement ◽  
Granulocytic Sarcoma ◽  
Molecular Response ◽  
Rare Type ◽  
Cytogenetic Remission

Myeloid or granulocytic sarcoma (GS) is a tumoral lesion consisting of immature granulocytic cells. It is a rare entity during the course of CML patients especially after allogeneic stem cell transplantation (SCT). Relapse without bone marrow involvement is much rarer. We report a case of CML patient who relapsed with isolated granulocytic sarcoma after allogeneic SCT during cytogenetic and molecular remission. 28-year-old male was diagnosed as CML and allogeneic SCT was performed because of refractory disease to tyrosine kinase inhibitors. Complete cytogenetic and molecular response was achieved after allogeneic SCT followed by dasatinib treatment. Approximately 5 years after the transplantation, very rapidly progressive lesion was documented and diagnosed as GS although he was at molecular and cytogenetic remission. The patient died during chemotherapy due to sepsis. GS relapse after allogeneic SCT is a very rare type of relapse in CML patients with molecular and cytogenetic remission. Since it is a very aggressive disease with a poor prognosis, combined chemoradiotherapies with other possible options like DLI or second allogeneic SCT should be considered as soon as the diagnosis is confirmed.

scholarly journals Granulocytic Sarcoma by AML M4eo (inv16) after Allogeneic Stem Cell Transplantation without Bone Marrow Involvement

2011 ◽  
Vol 2011 ◽  
pp. 1-3 ◽  
Author(s):  
Stephan Zaenker ◽  
Stefan Schweyer ◽  
Justin Hasenkamp ◽  
Lorenz Truemper ◽  
Gerald Wulf
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Bone Marrow Involvement ◽  
Granulocytic Sarcoma ◽  
Intrathecal Chemotherapy ◽  
Cellular Immunotherapy ◽  
Rare Type ◽  
Atypical Manifestations

Granulocytic sarcoma (GS) represents a rare type of extramedullar manifestation from the acute myeloid leukaemia (AML). We report the case of a patient with recurrences of AML M4eo leukaemia in the uterus and the small intestine at 3 and 5 years, respectively, after matched related peripheral blood stem cell transplantation (PBSCT). The patient underwent the withdrawal of immunosuppression, hysterectomy, and local irradiation at first relapse, as well as systemic chemotherapy and donor lymphocyte infusions at second recurrence, inducing a second and third complete remission, respectively. At year six after transplantation, the patient experienced disease progression by meningeosis leukaemia to which she succumbed despite intrathecal chemotherapy. Following allogeneic stem cell transplantation, awareness for atypical manifestations of granulocytic sarcoma appears prudent, the cellular immunotherapy should aim at immunological disease control.

False-Positive [18F]Fluorodeoxyglucose-Avid Lymph Nodes on Positron Emission Tomography–Computed Tomography After Allogeneic but Not Autologous Stem-Cell Transplantation in Patients With Lymphoma

2014 ◽  
Vol 32 (1) ◽  
pp. 51-56 ◽  
Author(s):  
Gary A. Ulaner ◽  
Joshua Lilienstein ◽  
Mithat Gönen ◽  
Jocelyn Maragulia ◽  
Craig H. Moskowitz ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Lymph Nodes ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Emission Tomography ◽  
Short Axis ◽  
Positron Emission ◽  
Pet Ct

Purpose Determine the clinical significance of [18F]fluorodeoxyglucose (FDG)–avid lesions in patients with lymphoma treated with stem-cell transplantation. Methods All patients who underwent stem-cell transplantation for lymphoma at Memorial Sloan-Kettering Cancer Center between January 2005 and December 2009 and had post-transplantation FDG positron emission tomography/computed tomography (PET/CT) examinations were included. PET/CT examinations were evaluated for FDG-avid lesions suggestive of disease. Clinical records, biopsy results, and subsequent imaging examinations were evaluated for malignancy. Results Two hundred fifty-one patients were identified, 107 with allogeneic and 144 with autologous stem-cell transplantation. Of allogeneic stem-cell transplantation recipients, 50 had FDG-avid lesions suggestive of lymphoma, defined as FDG-avidity greater than liver background. However, only 29 of these 50 demonstrated lymphoma on biopsy, whereas biopsy attempts were benign in the other 21 patients. Sensitivity analysis determined that a 1.5-cm short axis nodal measurement distinguished patients with malignant from nonmalignant biopsies. In 21 of 22 patients with FDG-avid lymph nodes ≤ 1.5 cm, biopsy attempts were benign. In the absence of treatment, these nodes either resolved or were stable on repeat imaging. Disease-free survival of patients with FDG-avid ≤ 1.5 cm lymph nodes was comparable with patients without FDG-avid lesions. In comparison, autologous stem-cell transplantation patients rarely demonstrated FDG-avid lesions suggestive of disease without malignant pathology. Conclusion Twenty percent (21 of 107) of patients with an allogeneic stem-cell transplantation demonstrated FDG-avid lymph nodes up to 1.5 cm in short axis on PET/CT, which did not represent active lymphoma. After allogeneic stem-cell transplantation of patients with lymphoma, benign FDG-avid ≤ 1.5 cm lymph nodes can mimic malignancy.

scholarly journals 18FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation

Oncotarget ◽  
2014 ◽  
Vol 5 (17) ◽  
pp. 7381-7391 ◽  
Author(s):  
Constantin Lapa ◽  
Katharina Lückerath ◽  
Uwe Malzahn ◽  
Samuel Samnick ◽  
Herrmann Einsele ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
18Fdg Pet ◽  
Pet Ct ◽  
Prognostic Stratification
Sign in / Sign up

Export Citation Format

Share Document